The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

Simultaneously, Bayer is making significant headway with its cancer medication Sevabertinib. The company has applied for regulatory approval in China, where the drug has already received the coveted ...

Note that some links may require registration or subscription. HHS Secretary Robert F. Kennedy Jr. is facing new questions ...

IMPROVING PATIENT DATA FLOW — The White House has gathered voluntary commitments from the health care industry to speed the ...

A coronary artery calcium test, a brief and painless CT scan, can would show whether the fatty deposits called plaque are ...

This regulatory update is a major milestone for Entera and the entire osteoporosis community,” said Miranda Toledano, CEO of Entera. “Our alignment with the FDA reflects the strength of our data and ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...